tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NURPF Stock Latest News

Neuren’s Phase 3 NNZ-2591 Trial Targets a High-Value Niche in Phelan-McDermid Syndrome
Company AnnouncementsNeuren’s Phase 3 NNZ-2591 Trial Targets a High-Value Niche in Phelan-McDermid Syndrome
3d ago
NURPF
Neuren Advances NNZ-2591 Program as Phase 2 PMS Data Published and Phase 3 Koala Trial Recruits in US
PremiumCompany Announcements
Neuren Advances NNZ-2591 Program as Phase 2 PMS Data Published and Phase 3 Koala Trial Recruits in US
4d ago
Neuren Wins Health Canada Nod to Expand Phase 3 Trial of NNZ-2591 in Phelan-McDermid Syndrome
PremiumCompany Announcements
Neuren Wins Health Canada Nod to Expand Phase 3 Trial of NNZ-2591 in Phelan-McDermid Syndrome
20d ago
Neuren Pharmaceuticals’ Partner Acadia Gains FDA Approval for New Rett Syndrome Treatment
PremiumCompany Announcements
Neuren Pharmaceuticals’ Partner Acadia Gains FDA Approval for New Rett Syndrome Treatment
27d ago
Neuren Pharmaceuticals Faces Delay in FDA Meeting for NNZ-2591
PremiumCompany Announcements
Neuren Pharmaceuticals Faces Delay in FDA Meeting for NNZ-2591
1M ago
Neuren Pharmaceuticals to Quote 150,000 New Securities on ASX
PremiumCompany AnnouncementsNeuren Pharmaceuticals to Quote 150,000 New Securities on ASX
2M ago
Neuren Pharmaceuticals: Advancing Neurodevelopmental Therapies Amidst Industry Challenges
Premium
Company Announcements
Neuren Pharmaceuticals: Advancing Neurodevelopmental Therapies Amidst Industry Challenges
2M ago
Neuren Pharmaceuticals Achieves Record DAYBUE™ Sales in Q3 2025
Premium
Company Announcements
Neuren Pharmaceuticals Achieves Record DAYBUE™ Sales in Q3 2025
2M ago
Neuren Pharmaceuticals Receives FDA Fast Track for NNZ-2591 in Phelan-McDermid Syndrome
PremiumCompany Announcements
Neuren Pharmaceuticals Receives FDA Fast Track for NNZ-2591 in Phelan-McDermid Syndrome
3M ago
Neuren Pharmaceuticals Expands Market Presence with New Securities Quotation
PremiumCompany Announcements
Neuren Pharmaceuticals Expands Market Presence with New Securities Quotation
3M ago
Neuren Pharmaceuticals Reports Strong Half-Year Earnings
PremiumCompany Announcements
Neuren Pharmaceuticals Reports Strong Half-Year Earnings
4M ago
Neuren Pharmaceuticals Partners with Hope for HIE to Develop New HIE Treatment
PremiumCompany Announcements
Neuren Pharmaceuticals Partners with Hope for HIE to Develop New HIE Treatment
4M ago
Neuren Pharmaceuticals CEO Adjusts Securities Interests, Boosting Market Position
PremiumCompany AnnouncementsNeuren Pharmaceuticals CEO Adjusts Securities Interests, Boosting Market Position
4M ago
Neuren Pharmaceuticals Quotes New Securities on ASX
Premium
Company Announcements
Neuren Pharmaceuticals Quotes New Securities on ASX
5M ago
Neuren Pharmaceuticals Focuses on Neurodevelopmental Disabilities
Premium
Company Announcements
Neuren Pharmaceuticals Focuses on Neurodevelopmental Disabilities
5M ago
Neuren Pharmaceuticals Reports Strong H1 2025 Results and Advances Drug Pipeline
PremiumCompany Announcements
Neuren Pharmaceuticals Reports Strong H1 2025 Results and Advances Drug Pipeline
5M ago
Neuren Pharmaceuticals Sees Robust Profit Growth Amid Strategic Buy-Back
PremiumCompany Announcements
Neuren Pharmaceuticals Sees Robust Profit Growth Amid Strategic Buy-Back
5M ago
Neuren Pharmaceuticals Initiates Phase 3 Trial for Phelan-McDermid Syndrome
PremiumCompany Announcements
Neuren Pharmaceuticals Initiates Phase 3 Trial for Phelan-McDermid Syndrome
5M ago
Neuren Pharmaceuticals Issues New Securities to Strengthen Market Position
PremiumCompany Announcements
Neuren Pharmaceuticals Issues New Securities to Strengthen Market Position
5M ago
Neuren Expands NNZ-2591 Pipeline to Include SYNGAP1-Related Disorder
PremiumCompany AnnouncementsNeuren Expands NNZ-2591 Pipeline to Include SYNGAP1-Related Disorder
5M ago
Neuren Pharmaceuticals Sees Robust Growth in DAYBUE Sales for Q2 2025
Premium
Company Announcements
Neuren Pharmaceuticals Sees Robust Growth in DAYBUE Sales for Q2 2025
5M ago
Neuren Pharmaceuticals Director’s Share Conversion
Premium
Company Announcements
Neuren Pharmaceuticals Director’s Share Conversion
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >